Abstract
Historically, patient access to investigational products (drugs or devices) has been limited to enrollment in clinical trials. However, enrollment of a patient into a clinical trial is not always possible for various reasons. Demand from patients and physicians for access to investigational products is due to the (sometimes remote) potential benefit to patients who have no other therapeutic alternatives.
There are various options for the use of investigational drugs and devices in patient treatment through the Food and Drug Administration’s (FDA) expanded access program. These are outlined, along with criteria for use, submission requirements, approval processes, and associated practical guidance.
There are four expanded access pathways for the use of investigational drugs: single-patient emergency use, single-patient treatment use, intermediate-size population treatment use, and treatment use. There are three expanded access pathways for the use of investigational devices: single-patient emergency use, single-patient or small group compassionate use, and treatment use. Additionally, treatment of a rare disease or condition with a Humanitarian Use Device (HUD) under a Humanitarian Device Exemption (HDE) is also possible.
References
101st U.S. Congress (1989) H.R. 3095: Safe Medical Devices Act of 1990. Accessed 2/9/2019 from https://www.govinfo.gov/content/pkg/STATUTE-104/pdf/STATUTE-104-Pg4511.pdf
97th U.S. Congress (1983) H.R. 5238: Orphan Drug Act. Accessed 2/9/2019 from https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf
United States (US) Department of Health and Human Services (DHHS) (2019) Security and privacy, 21 CFR Part 164. Washington, DC.
United States (US) Department of Health and Human Services (DHHS) (2019) General administrative requirements, 21 CFR Part 160. Washington, DC
United States (US) Food and Drug Administration (FDA) (2010) Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff – Humanitarian Device Exemption (HDE) Regulation: Questions and Answers. Accessed 2/9/2019 from: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/HumanitarianDeviceExemption/ucm563322.htm
United States (US) Food and Drug Administration (FDA) (2018a) Humanitarian use devices, 21 CFR Part 814, Subpart H. Washington, DC
United States (US) Food and Drug Administration (FDA) (2018b) Institutional review boards, 21 CFR Part 56. Washington, DC
United States (US) Food and Drug Administration (FDA) (2018c) Investigational device exemptions, 21 CFR Part 812. Washington, DC
United States (US) Food and Drug Administration (FDA) (2018d) IDE Reports. https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm046717.htm. Accessed 3/10/2019
United States (US) Food and Drug Administration (FDA) (2018e) Medical device reporting, 21 CFR Part 803. Washington, DC
United States (US) Food and Drug Administration (FDA) (2018f) Protection of human subjects, 21 CFR Part 50. Washington, DC
United States (US) Food and Drug Administration (FDA) (2018g) Expanded access for medical devices. Washington, DC
United States (US) Food and Drug Administration (FDA) (2018h) Supplemental applications, 21 CFR part 812.35. Washington, DC
United States (US) Government Publishing Office (GPO) (2016) 21st Century Cures Act (Public Law 114–255). Washington, DC. Accessed 2/9/2019 from http://www.congress.gov
Van Norman GA (2018) Expanding patient access to investigational drugs: single patient investigational new drug and the “Right to try.” JACC Basic Transl Sci 3(2):280–293. https://doi.org/10.1016/j.jacbts.2017.11.007
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Ziolek, T., Yoos, J.L., Strakovsky, I., Shah, P., Robison, E. (2021). Expanded Access to Drug and Device Products for Clinical Treatment. In: Piantadosi, S., Meinert, C.L. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_172-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52677-5_172-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52677-5
Online ISBN: 978-3-319-52677-5
eBook Packages: Springer Reference MathematicsReference Module Computer Science and Engineering